Clinical Trial

Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated January 15, 2026 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This phase III trial studies how well bupropion works in reducing cancer related fatigue in cancer survivors. Cancer and its treatment can cause fatigue. Bupropion is a drug that is used to treat depression, as well as to help people quit smoking. It belongs to the family of drugs called antidepressants and works by increasing certain types of activity in the brain. Bupropion may reduce cancer-related fatigue by causing changes in inflammation and stress hormones.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2019-06-21; most recent amendment 2026-01-14.
Status change: Recruiting → Active, Not Recruiting 2026-01-14
Trial Details
NCT Number NCT03996265
Lead Sponsor University of Rochester NCORP Research Base
Collaborators: National Cancer Institute (NCI)
Conditions Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Enrollment 422 participants
Start Date 2019-06-27
Primary Completion 2026-05-30 (estimated)
Study Completion 2026-08-05 (estimated)
Updated on ClinicalTrials.gov 2026-01-15